AERA-109 / Aera Therapeutics - LARVOL DELTA

Aera Therapeutics to Present Preclinical Data on AERA-109, a Targeted In Vivo CAR-T Therapy for B Cell-mediated Autoimmune Diseases, at the 67th American Society of Hematology (ASH) Annual Meeting (Businesswire) - "Preclinical data to be presented in the poster demonstrate potent and durable B cell depletion from the periphery and B cell rich tissues, including the spleen, bone marrow and lymph nodes, in non-human primate with AERA-109 at doses as low as 0.3 mg/kg....'We are excited to advance AERA-109 as a next-generation treatment for patients with B cell-mediated autoimmune diseases and expect to enter clinical development in mid-2026'."

New trial • Preclinical • Immunology